Table 3.
Association of late follow-up 25-hydroxyvitamin-D3 and peritransplant 1,25-dihydroxyvitamin-D3 levels with TRM.
| Model | 25(OH)D3 late follow-up (day 32 to 100) | 1,25(OH)2D3 peritransplant (day −2 to 7) | ||||
|---|---|---|---|---|---|---|
| #at risk/ #TRM | HR (95% CI) | P | #at risk/#TRM | HR (95% CI) | P | |
| Unadjusted | 88/17 | 143/23 | ||||
| Serum level | 0.98 (0.97; 0.99) | 0.001 | 0.99 (0.99; 1.00) | 0.001 | ||
| Adjusted I | 77/16 | 128/21 | ||||
| Serum level | [nM] | 0.98 (0.97; 0.99) | 0.004 | [pM] | 0.99 (0.98, 1.00) | 0.002 |
| Age [yr] | 1.08 (1.00; 1.16) | 0.030 | 1.08 (1.02; 1.15) | 0.013 | ||
| Male sex | 0.57 (0.19; 1.71) | 0.314 | 0.45 (0.18; 1.13) | 0.089 | ||
| Unrelated donora | 0.61 (0.20; 1.89) | 0.390 | 1.04 (0.39; 2.82) | 0.935 | ||
| Late tumor stageb | 1.81 (0.66; 4.98) | 0.250 | 1.82 (0.75; 4.41) | 0.186 | ||
| Adjusted II | 77/16 | 128/21 | ||||
| Serum level | [nM] | 0.99 (0.98, 1.00) | 0.069 | [pM] | 0.99 (0.96; 1.00) | 0.005 |
| Age [yr] | 1.05 (0.98; 1.13) | 0.139 | 1.05 (0.99; 1.12) | 0.087 | ||
| Sex | 0.86 (0.26; 2.81) | 0.803 | 1.40 (0.48; 4.07) | 0.538 | ||
| Unrelated donora | 0.53 (0.16; 1.72) | 0.287 | 0.86 (0.30; 2.45) | 0.774 | ||
| Late tumor stageb | 2.04 (0.72; 5.84) | 0.182 | 1.72 (0.68; 4.31) | 0.250 | ||
| Severe aGvHDc | 4.56 (1.35; 15.39) | 0.015 | 14.81 (5.09; 43.08) | <0.0005 | ||
| Adjusted III | 77/16 | 128/21 | ||||
| Serum level | [nM] | 0.99 (0.96, 1.00) | 0.068 | [pM] | 0.99 (0.99; 1.00) | 0.005 |
| Age [yr] | 1.05 (0.98; 1.13) | 0.144 | 1.05 (0.99; 1.12) | 0.090 | ||
| Sex | 0.86 (0.26; 2.82) | 0.808 | 1.37 (0.46; 4.12) | 0.576 | ||
| Unrelated donora | 0.52 (0.16; 1.72) | 0.286 | 0.85 (0.29; 2.44) | 0.756 | ||
| Late tumor stageb | 2.03 (0.70; 5.88) | 0.194 | 1.73 (0.69; 4.34) | 0.247 | ||
| Severe aGvHDc | 4.56 (1.35; 15.44) | 0.015 | 14.81 (5.08; 43.13) | <0.0005 | ||
| 25(OH)D3 d-2–7d | [nM] | 1.00 (0.97; 1.03) | 0.929 | [pM] | 1.00 (0.98; 1.02) | 0.871 |
Shown are results from Cox proportional hazards models for the association of late follow-up 25-hydroxyvitamin-D3 (25(OH)D3, day 32 to 100) or peritransplant 1,25-dihydroxyvitamin-D3 (1,25(OH)2D3, day −2 to 7) with TRM without and with adjustment for risk factors and sensitivity analyses. P values ≤0.05 are marked in bold.
TRM treatment-related mortality, 25(OH)D3 25-hydroxyvitamin-D3, 1,25(OH)2D3 1,25-dihydroxyvitamin-D3, HR hazard ratio, aGvHD acute Graft-versus-Host disease.
aPatients with unrelated donors versus patients with sibling donors.
bClassification according to EBMT risk score [50] late stage versus early/intermediate stage.
cAny occurrence of aGvHD 3–4 [14] within 1 year after HSCT versus no occurrence of aGvHD 3–4.
dPeritransplant (day −2 to 7) 25-hydroxyvitamin-D3.